Bullish Case: Momentum is real: +30% over 90 days and +12% in a week, backed by raised FY26 guidance, 81% Recorlev growth, and strong Q margins. Helium's forward density peaks at $10–$11 with density extending toward $14–$16. Jan/ Apr 2027 call IV (48–74%) sits well below near-dated IV, implying the market sees sustained drift rather than an imminent shock; a Q3 beat or XP-8121 Phase 3 progress could carry $12–$14.

Bearish Case: After a 24% one-month run, mean reversion risk is high: the return surface's densest historical bands favor modest, not parabolic, returns, and thin options liquidity (8th percentile volume, put-led flow) signals fragile positioning. Near-dated IV is elevated and backwardated, SPY's surface prices fat downside tails, and any cautious XP-8121/regulatory wording or guidance trim could produce a sharp -10–20% snap toward $9.

Potential Outcomes:

1. ~35%: Continuation/drift toward $11.50–$13 on Q3 execution and XP-8121 progress; falsifiable if price stalls below $10.50 by mid-Nov.
2. ~25%: Consolidation $10–$11.50; no new filings/news through year-end.
3. ~20%: Mean-reversion pullback to $9–$10 after the +24% month; falsifiable if $10 support holds on volume.
4. ~12%: Earnings/regulatory caution or XP-8121 delay → $8–$9.50.
5. ~8%: Macro SPY shock plus IV spike → below $8.50.

Reflection: prior M&A calls (12–20%) repeatedly failed their test dates — downweight takeover scenarios; chop/mean-reversion calls were the most accurate.

October 21, 2026